Related Experiment Video

Updated: Dec 16, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.6K

SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation

Manon Grandbastien1, Anays Piotin1, Julien Godet2

  • 1Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France.

The Journal of Allergy and Clinical Immunology. in Practice
|July 1, 2020
PubMed
Abstract

Insights

Patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia did not experience severe exacerbations. COVID-19 pneumonia did not appear to increase the risk of severe outcomes in asthma patients.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Allergy and Immunology

Background:

  • Viral infections are known asthma exacerbators in adults.
  • Limited data exists on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severe asthma exacerbation.
  • The impact of SARS-CoV-2 pneumonia on asthma patients requires investigation.

Purpose of the Study:

  • To determine the frequency of asthma exacerbation in hospitalized SARS-CoV-2 pneumonia patients.
  • To compare clinical, laboratory, and radiological findings between asthma and non-asthma SARS-CoV-2 pneumonia patients.
  • To evaluate the relationship between SARS-CoV-2 infection and severe asthma exacerbation.

Main Methods:

  • A cohort of 106 patients hospitalized with SARS-CoV-2 pneumonia was studied.
  • Asthma status was assessed in the month prior to symptoms, pre-hospitalization, and during hospitalization.
  • Severe asthma exacerbations were defined per Global Initiative for Asthma guidelines and clinical criteria.

Main Results:

  • No significant differences in severity metrics (e.g., length of stay, ICU transfer) were observed between asthma and non-asthma groups.
  • Only a small proportion of asthma patients experienced exacerbations or required systemic corticosteroids during hospitalization.
  • 52.2% of asthma patients had Global Initiative for Asthma step 1 asthma.

Conclusions:

  • Asthma patients hospitalized with SARS-CoV-2 pneumonia do not appear to be at increased risk for severe disease.
  • SARS-CoV-2 pneumonia did not precipitate severe asthma exacerbations in this cohort.
  • Further research may clarify the specific interactions between asthma and COVID-19.
Keywords:
AsthmaCOVID-19CoronavirusEuropeExacerbationFranceSARS-CoV-2SARS-CoV-2 pneumonia

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.0K
Experimental Model to Evaluate Resolution of Pneumonia09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

1.7K

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.3K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.1K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
876